Age, y
|
71 ± 7
|
71 ± 8
|
71 ± 7
|
Men, n (%)
|
17 (57)
|
7 (35)
|
24 (48)
|
NYHA II/III, n (%)
|
20/10 (67/33)
|
13/7 (65/35)
|
33/17 (66/34)
|
Systolic blood pressure, mm Hg
|
130 ± 14
|
127 ± 12
|
129 ± 13
|
Diastolic blood pressure, mm Hg
|
80 ± 11
|
76 ± 10
|
78 ± 11
|
Heart rate, bpm
|
63 ± 8
|
63 ± 7
|
63 ± 7
|
Body mass index, kg/m2
|
30 ± 6
|
29 ± 4
|
30 ± 5
|
Overweight/obesity (body mass index ≥25 kg/m2), n (%)
|
26 (87)
|
18 (90)
|
44 (88)
|
Hypertension (blood pressure ≥ 140/90 mmHg), n (%)
|
30 (100)
|
20 (100)
|
50 (100)
|
Paroxysmal atrial fibrillation, n (%)
|
10 (33)
|
5 (25)
|
15 (30)
|
Ischemic heart disease, n (%)
|
15 (50)
|
7 (35)
|
22 (44)
|
Previous myocardial infarction, n (%)
|
9 (30)
|
4 (20)
|
13 (26)
|
Myocardial revascularization, n (%)
|
11 (37)
|
4 (20)
|
15 (30)
|
Diabetes mellitus, n (%)
|
10 (33)
|
4 (20)
|
14 (28)
|
Chronic kidney disease, n (%)
|
26 (87)
|
14 (70)
|
40 (80)
|
Drug therapy:
|
ACEI/ARB, n (%)
|
30 (100)
|
20 (100)
|
50 (100)
|
β-Blockers, n (%)
|
21 (70)
|
18 (90)
|
39 (78)
|
Diuretics, n (%)
|
28 (93)
|
19 (95)
|
47 (94)
|
Thiazide diuretics, n (%)
|
2 (7)
|
2 (10)
|
4 (8)
|
Loop diuretics, n (%)
|
26 (87)
|
17 (85)
|
34 (86)
|
Spironolactone, n (%)
|
6 (20)
|
2 (10)
|
8 (16)
|
Calcium channel blockers, n (%)
|
15 (50)
|
7 (35)
|
22 (44)
|
Statins, n (%)
|
26 (87)
|
18 (90)
|
44 (88)
|
LV ejection fraction, %
|
60 ± 5
|
61 ± 6
|
61 ± 5
|
LV hypertrophy, n (%)
|
20 (67)
|
15 (75)
|
35 (70)
|
PA systolic pressure, mm Hg
|
58.6 ± 14.9
|
55.5 ± 13.5
|
57.3 ± 14.3
|
Increased RA pressure, n (%)
|
26 (87)
|
14 (70)
|
40 (80)
|
RV systolic dysfunction, n (%)
|
22 (73)
|
10 (50)
|
32 (64)
|
PVR, Wood units
|
3.33 ± 0.64
|
3.19 ± 0.47
|
3.27 ± 0.58
|
TPG, mm Hg
|
23.3 ± 7.7
|
22.1 ± 8.8
|
22.8 ± 8.1
|
Mitral Е/e′ ratio
|
14.2 ± 4.2
|
12.6 ± 3.7
|
13.6 ± 4.0
|
LV diastolic dysfunction, grade II/III, n (%)
|
19/11 (64/36)
|
14/6 (70/30)
|
33/17 (66/34)
|
NT-proBNP, pg/mL
|
391 (190—582)
|
468 (205—720)
|
408 (194—631)
|